Q32 Bio receives a 'Buy' rating due to advancements in its alopecia treatment bempikibart and upcoming clinical trial data expected by mid-2026. The company secured $55 million in private funding, extending its cash runway into the first half of 2028, supporting continued development milestones. Additionally, a $12 million upfront payment and potential $592 million in milestones from the sale of ADX-097 to Akebia bolster its financial position while retaining key assets. These factors position Q32 Bio for potential growth in the biotech sector.
Christopher Derrick, known for writing on Star Trek: Picard and The Equalizer, premieres his first film as sole writer-director, Moral Dirt, at the Academy Award® Qualifying LA Shorts International Film Festival on August 3, 2026. The 15-minute psych...
Arcutis Biotherapeutics has appointed Chris Peetz to its Board of Directors as of July 15, 2026. Peetz brings extensive experience leading biopharmaceutical companies through growth phases, product development, and strategic acquisitions. His additio...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
